About Aliyah Sohani, MD

Dr. Sohani is a board-certified pathologist in Anatomic and Clinical Pathology and Hematology and her areas of clinical focus include Hematopathology, Surgical Pathology, and Laboratory Hematology. She currently serves as the Associate Chief for Clinical Affairs and the Director of Surgical Pathology, providing medical oversight for the MGH Anatomic Pathology laboratories that process tissue biopsies and surgical resection specimens. Previously, she directed the Hematology section of the MGH Core Laboratory, the hospital’s largest clinical laboratory. She has led these laboratories through major policy and operational changes that have resulted in workflow improvements and diagnostic enhancements benefiting the hospital, its patients and employees. 

Dr. Sohani is active in educating pathologists and trainees locally and internationally. She has received the Clinical Pathology Excellence in Teaching Award from MGH Pathology trainees three times since 2008 and her teaching contributions extend to pathologists practicing in low- and middle-income countries (LMICs). She has developed an educational support network, consults in a voluntary capacity on challenging hematopathology cases, and leads several academic collaborations with pathologists based in LMICs. These initiatives have spawned numerous publications, fostering the career development of mentees both regionally and abroad. She co-chairs the MGH Pathology Diversity, Equity, Inclusion and Professionalism (DEIP) Committee and her efforts have helped to identify strategic priorities for MGH Pathology in the areas of community outreach, employee retention and development, and trainee and junior faculty recruitment and development.  

Dr. Sohani is a nationally and internationally known and respected hematopathologist, speaking frequently on lymphoma-related topics around the world. She serves on the editorial boards of several journals in the fields of hematology and hematopathology and has contributed to diagnostic and clinical care guidelines published by the NIH, FDA, WHO, and National Comprehensive Cancer Network (NCCN). Dr. Sohani has also contributed to the development of guidelines for lymphoma diagnosis and prognosis in regions of the world with limited testing resources and is exploring ways that telemedicine and web-based learning can be used to enhance the delivery of pathology services in resource-limited settings to provide educational support to pathologists practicing in LMICs.

Clinical Interests:



Mass General Pathology
55 Fruit St.
Boston, MA 02114
Phone: 617-643-0800

Medical Education

  • MD, Harvard Medical School (Massachusetts)
  • Residency, Massachusetts General Hospital
  • Fellowship, Massachusetts General Hospital

American Board Certifications

  • Anatomic Pathology and Clinical Pathology, American Board of Pathology
  • Hematopathology, American Board of Pathology

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


Dr. Sohani's academic activities have focused on the classification and characterization of various lymphoma subtypes, including rare and difficult-to-study lymphoid malignancies. Her research has identified morphologic, immunologic, and genetic features of these tumors that further the understanding of their pathogenesis, define accurate diagnostic criteria, and serve to predict tumor behavior and response to therapy. These efforts have led to the contribution of new knowledge and several key innovations to the field of lymphoma diagnosis and classification, including the first description of unusual, non-neoplastic T-cell populations in nodular lymphocyte predominant Hodgkin lymphoma; improved methods of screening for and diagnosing aggressive high-grade B-cell lymphomas with MYC and BCL2 rearrangements (double-hit lymphoma); improved diagnostic guidelines related to recognition by pathologists of rare cases of extranodal NK/T-cell lymphoma with deceptively bland cytomorphology; immunophenotypic and genetic evidence supporting the distinct pathogenesis of EBV-negative vs. EBV+ monomorphic post-transplant lymphoproliferative disorder; and development of an immunohistochemistry-based biologic risk score in primary mediastinal large B-cell lymphoma.


Reviews: Comments and Ratings